Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.
Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.
复制标题
DOI：
10.14670/hh-18-175
复制
发表时间：
2020-04
影响因子：
2
通讯作者：
A. Zheng;Lin Zhang;Xinyue Song;F. Jin
中科院分区：
文献类型：
--
作者：
A. Zheng;Lin Zhang;Xinyue Song;F. Jin
乳腺癌是女性最常见的恶性肿瘤，也是女性癌症死亡的主要原因。长非编码RNA(LncRNAs)作为新的癌症预后生物标志物正在研究中。本研究的目的是探讨乳腺癌新辅助化疗(NACT)患者中lncRNA SPRY4-IT1的表达、临床意义及预后意义，并探讨SPRY4-IT1对乳腺癌化疗结果的预测价值。生物信息学研究表明，SPRY4-IT1与乳腺癌的化疗耐药有关。采用定量逆转录聚合酶链式反应(qRT-PCR)检测SPRY4-IT1在乳腺癌组织和配对正常乳腺组织(n=26)中的表达。应用原位杂交技术检测60例临床资料完整的石蜡切片中SPRY4-IT1的表达。在本研究中，SPRY4-IT1在癌组织中的表达显著高于在正常组织中的表达(P<；0.05)。SPRY4-IT1的高表达与淋巴结转移率(P=0.002)和复发率(P=0.017)显著相关。两者均为影响SPRY4-IT1表达的独立因素(P<；0.05)。高SPRY4-IT1患者的总存活率和无病存活率显著降低。SPRY4-IT1高表达提示全组、腔A亚组和腔B亚组临床反应差(P<；0.05)，全组病理完全反应。SPRY4-IT1过表达促进了MCF-7和MDA-MB-231细胞对表阿霉素的耐药性。SPRY4-IT1有可能成为预测乳腺癌患者NACT疗效和预后的生物标志物。
Breast cancer is the most frequent malignancy and the leading cause of cancer death among females. Long noncoding RNAs (lncRNAs) are under investigation as novel prognostic biomarkers in cancer. The aim of the study was to investigate the expression, clinical implications and prognostic significance of lncRNA SPRY4-IT1, and to identify the predictive value of SPRY4-IT1 on the outcome of chemotherapy in breast cancer patients undergoing neoadjuvant chemotherapy (NACT). Bioinformatics indicated SPRY4-IT1 was related to chemo-resistance in breast cancer. SPRY4-IT1 expression was assessed by qRT-PCR in breast cancer tissues and matched normal breast tissues (n=26 pairs). SPRY4-IT1 expression was also detected by In situ hybridization (ISH) in 60 paraffin slices with complete clinical datum. In this study, SPRY4-IT1 was significantly more expressed in cancer tissues than in normal tissues (P<0.05). Increased SPRY4-IT1 expression was significantly corre¬lated with increased rates of lymph node metastasis (P=0.002) and recurrence (P=0.017). Both were independent factors of SPRY4-IT1 expression (P<0.05). High-SPRY4-IT1 patients had significantly lower overall survival and disease-free survival. High SPRY4-IT1 expression indicated poor clinical response in the whole group, luminal A subgroup and luminal B subgroup (P<0.05) and pathological complete response in the whole group. Overexpression of SPRY4-IT1 promoted chemo-resistance of MCF-7 and MDA-MB-231 cells to epirubicin. SPRY4-IT1 has the potential to be a biomarker to predict NACT efficacy and prognosis in breast cancer patients.